drugset / Trial / NCT00702845

To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)

NCT00702845

Phase 3 Completed 397 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

Clinical trial objectives are to investigate the efficacy and safety of a single injection of 100 μg Org 36286 in women weighing 60 kg or less to induce multifollicular development for controlled ovarian stimulation (COS), using daily recFSH as a reference.

Timeline

Start
2006-12-28
Primary completion
2007-07-07
Completion
2007-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Corifollitropin alfa Protein / enzyme biologic 100 ug Subcutaneous
Comparator recFSH (follitropin beta) Protein / enzyme biologic 150 iu Subcutaneous
Background Follitropin beta Protein / enzyme biologic 200 iu
Background Ganirelix Protein / enzyme biologic 0.25 mg Subcutaneous
Background Progesterone Other / unclassified 50 mg Other
Background Progesterone Other / unclassified 600 mg Other
Background human chorion gonadatropin (hCG) Unknown 5000 iu Subcutaneous
Background human chorion gonadatropin (hCG) Unknown 10000 iu Subcutaneous

Indications